메뉴 건너뛰기




Volumn 38, Issue 3, 2014, Pages 211-219

The effect of DPP-4 inhibitors on metabolic parameters in patients with type 2 diabetes

Author keywords

Diabetes mellitus; DPP 4 inhibitor; Glycated serum albumin; Lipids

Indexed keywords

C REACTIVE PROTEIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SITAGLIPTIN; TRIACYLGLYCEROL; VILDAGLIPTIN;

EID: 84903828239     PISSN: 22336079     EISSN: 22336087     Source Type: Journal    
DOI: 10.4093/dmj.2014.38.3.211     Document Type: Article
Times cited : (27)

References (33)
  • 1
    • 84858702540 scopus 로고    scopus 로고
    • The worldwide epidemiology of type 2 diabetes mellitus: present and future perspectives
    • Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus: present and future perspectives. Nat Rev Endocrinol 2012;8:228-36.
    • (2012) Nat Rev Endocrinol , vol.8 , pp. 228-236
    • Chen, L.1    Magliano, D.J.2    Zimmet, P.Z.3
  • 2
    • 77953037470 scopus 로고    scopus 로고
    • Diabetes type 2 pandemic in 21st century
    • Ginter E, Simko V. Diabetes type 2 pandemic in 21st century. Bratisl Lek Listy 2010;111:134-7.
    • (2010) Bratisl Lek Listy , vol.111 , pp. 134-137
    • Ginter, E.1    Simko, V.2
  • 4
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
    • UK Prospective Diabetes Study (UKPDS) Group
    • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837-53.
    • (1998) Lancet , vol.352 , pp. 837-853
  • 9
    • 77953627761 scopus 로고    scopus 로고
    • Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus
    • Iwamoto Y, Taniguchi T, Nonaka K, Okamoto T, Okuyama K, Arjona Ferreira JC, Amatruda J. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J 2010;57:383-94.
    • (2010) Endocr J , vol.57 , pp. 383-394
    • Iwamoto, Y.1    Taniguchi, T.2    Nonaka, K.3    Okamoto, T.4    Okuyama, K.5    Arjona Ferreira, J.C.6    Amatruda, J.7
  • 11
    • 77958540127 scopus 로고    scopus 로고
    • Vildagliptin: a review of its use in type 2 diabetes mellitus
    • Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 2010;70:2089-112.
    • (2010) Drugs , vol.70 , pp. 2089-2112
    • Keating, G.M.1
  • 14
    • 84863436536 scopus 로고    scopus 로고
    • Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors
    • Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet 2012;51:501-14.
    • (2012) Clin Pharmacokinet , vol.51 , pp. 501-514
    • Golightly, L.K.1    Drayna, C.C.2    McDermott, M.T.3
  • 15
    • 84863115894 scopus 로고    scopus 로고
    • Clinical pharmacokinetics and pharmacodynamics of vildagliptin
    • He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet 2012;51:147-62.
    • (2012) Clin Pharmacokinet , vol.51 , pp. 147-162
    • He, Y.L.1
  • 17
    • 84866645242 scopus 로고    scopus 로고
    • Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition
    • Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-82.
    • (2012) Diabetes Care , vol.35 , pp. 2076-2082
    • Rizzo, M.R.1    Barbieri, M.2    Marfella, R.3    Paolisso, G.4
  • 18
    • 84875054251 scopus 로고    scopus 로고
    • Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors
    • Barbieri M, Rizzo MR, Marfella R, Boccardi V, Esposito A, Pansini A, Paolisso G. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis 2013;227:349-54.
    • (2013) Atherosclerosis , vol.227 , pp. 349-354
    • Barbieri, M.1    Rizzo, M.R.2    Marfella, R.3    Boccardi, V.4    Esposito, A.5    Pansini, A.6    Paolisso, G.7
  • 20
    • 33846817233 scopus 로고    scopus 로고
    • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
    • Sitagliptin Study 024 Group
    • Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205.
    • (2007) Diabetes Obes Metab , vol.9 , pp. 194-205
    • Nauck, M.A.1    Meininger, G.2    Sheng, D.3    Terranella, L.4    Stein, P.P.5
  • 21
    • 33845476757 scopus 로고    scopus 로고
    • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
    • Sitagliptin Study 020 Group
    • Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43.
    • (2006) Diabetes Care , vol.29 , pp. 2638-2643
    • Charbonnel, B.1    Karasik, A.2    Liu, J.3    Wu, M.4    Meininger, G.5
  • 23
    • 84859174317 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis
    • Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012;344:e1369.
    • (2012) BMJ , vol.344
    • Karagiannis, T.1    Paschos, P.2    Paletas, K.3    Matthews, D.R.4    Tsapas, A.5
  • 24
    • 84873873967 scopus 로고    scopus 로고
    • Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus
    • Kothny W, Foley J, Kozlovski P, Shao Q, Gallwitz B, Lukashevich V. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:252-7.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 252-257
    • Kothny, W.1    Foley, J.2    Kozlovski, P.3    Shao, Q.4    Gallwitz, B.5    Lukashevich, V.6
  • 25
    • 84875370840 scopus 로고    scopus 로고
    • Efficacy of vildagliptin on glucose fluctuation in Japanese type 2 diabetic patients with ongoing sulfonylurea based oral glycemic agent therapy
    • Yoshioka K, Isotani H, Ohashi S, Imamura M. Efficacy of vildagliptin on glucose fluctuation in Japanese type 2 diabetic patients with ongoing sulfonylurea based oral glycemic agent therapy. Diabetes Metab Syndr 2013;7:32-4.
    • (2013) Diabetes Metab Syndr , vol.7 , pp. 32-34
    • Yoshioka, K.1    Isotani, H.2    Ohashi, S.3    Imamura, M.4
  • 26
    • 84879996784 scopus 로고    scopus 로고
    • Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes
    • Oh TJ, Jung HS, Bae JH, Kim YG, Park KS, Cho YM, Park KS, Kim SY. Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes. J Korean Med Sci 2013;28:881-7.
    • (2013) J Korean Med Sci , vol.28 , pp. 881-887
    • Oh, T.J.1    Jung, H.S.2    Bae, J.H.3    Kim, Y.G.4    Park, K.S.5    Cho, Y.M.6    Park, K.S.7    Kim, S.Y.8
  • 27
    • 77957740531 scopus 로고    scopus 로고
    • Clinical impact of glycated albumin as another glycemic control marker
    • Koga M, Kasayama S. Clinical impact of glycated albumin as another glycemic control marker. Endocr J 2010;57:751-62.
    • (2010) Endocr J , vol.57 , pp. 751-762
    • Koga, M.1    Kasayama, S.2
  • 28
    • 84864619348 scopus 로고    scopus 로고
    • The roles of glycated albumin as intermediate glycation index and pathogenic protein.
    • Kim KJ, Lee BW. The roles of glycated albumin as intermediate glycation index and pathogenic protein. Diabetes Metab J 2012; 36:98-107.
    • Diabetes Metab J 2012 , vol.36 , pp. 98-107
    • Kim, K.J.1    Lee, B.W.2
  • 29
    • 84866674568 scopus 로고    scopus 로고
    • Glycated albumin is superior to hemoglobin A1c for evaluating the presence and severity of coronary artery disease in type 2 diabetic patients
    • Shen Y, Pu LJ, Lu L, Zhang Q, Zhang RY, Shen WF. Glycated albumin is superior to hemoglobin A1c for evaluating the presence and severity of coronary artery disease in type 2 diabetic patients. Cardiology 2012;123:84-90.
    • (2012) Cardiology , vol.123 , pp. 84-90
    • Shen, Y.1    Pu, L.J.2    Lu, L.3    Zhang, Q.4    Zhang, R.Y.5    Shen, W.F.6
  • 30
    • 80051553874 scopus 로고    scopus 로고
    • Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials
    • Signorovitch JE, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger JB. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials. Clin Drug Investig 2011;31:665-74.
    • (2011) Clin Drug Investig , vol.31 , pp. 665-674
    • Signorovitch, J.E.1    Wu, E.Q.2    Swallow, E.3    Kantor, E.4    Fan, L.5    Gruenberger, J.B.6
  • 33
    • 84857903646 scopus 로고    scopus 로고
    • DPP-4 inhibitors and lipids: systematic review and meta-analysis
    • Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther 2012;29:14-25.
    • (2012) Adv Ther , vol.29 , pp. 14-25
    • Monami, M.1    Lamanna, C.2    Desideri, C.M.3    Mannucci, E.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.